Here, we demonstrate that removing p16+ senescent cells has a positive impact on the efficacy of hypofractionated RT combined with P in a highly translational model of HR+ breast cancer, but only when RT and P are combined according to the P→RT schedule (Fig. 1). Here, CDKN2A is linked to breast carcinoma.